Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Notes Payables (2018 - 2022)

Historic Notes Payables for Inspire Medical Systems (INSP) over the last 3 years, with Q2 2022 value amounting to $12.2 million.

  • Inspire Medical Systems' Notes Payables rose 29993.47% to $12.2 million in Q2 2022 from the same period last year, while for Jun 2022 it was $12.2 million, marking a year-over-year increase of 29993.47%. This contributed to the annual value of $9.2 million for FY2021, which is N/A changed from last year.
  • As of Q2 2022, Inspire Medical Systems' Notes Payables stood at $12.2 million, which was up 29993.47% from $12.2 million recorded in Q1 2022.
  • Over the past 5 years, Inspire Medical Systems' Notes Payables peaked at $12.2 million during Q1 2022, and registered a low of $681000.0 during Q1 2018.
  • For the 3-year period, Inspire Medical Systems' Notes Payables averaged around $6.6 million, with its median value being $6.1 million (2021).
  • Within the past 5 years, the most significant YoY rise in Inspire Medical Systems' Notes Payables was 29993.47% (2022), while the steepest drop was 29993.47% (2022).
  • Over the past 3 years, Inspire Medical Systems' Notes Payables (Quarter) stood at $2.7 million in 2018, then skyrocketed by 237.55% to $9.2 million in 2021, then surged by 33.33% to $12.2 million in 2022.
  • Its Notes Payables was $12.2 million in Q2 2022, compared to $12.2 million in Q1 2022 and $9.2 million in Q4 2021.